Lipella Pharmaceuticals Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Lipella Pharmaceuticals Inc. (LIPO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$329.09 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-11-14
- Lipella Pharmaceuticals Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $2.04M.
- Lipella Pharmaceuticals Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$1.19M.
- Lipella Pharmaceuticals Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$1.10M.
- Lipella Pharmaceuticals Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$999.43K.
- Lipella Pharmaceuticals Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$1.11M.
- Lipella Pharmaceuticals Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$1.83M, a 149.30% decline from fiscal 2022.
- Lipella Pharmaceuticals Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $3.71M, a 359.42% increase from fiscal 2021.
- Lipella Pharmaceuticals Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $807.09K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | -$329.09K 10-Q · filed 2025-11-14 | ||||||
| 2025-06-30 | $596.97K 10-Q · filed 2025-08-14 | ||||||
| 2025-03-31 | $2.04M 10-Q · filed 2025-05-14 | ||||||
| 2024-12-31 | -$1.11M 10-K · filed 2025-03-28 | ||||||
| 2024-09-30 | -$1.94M 10-Q · filed 2025-11-14 | -$1.94M 10-Q · filed 2024-11-14 | |||||
| 2024-06-30 | -$2.11M 10-Q · filed 2025-08-14 | -$2.11M 10-Q · filed 2024-08-13 | |||||
| 2024-03-31 | -$1.19M 10-Q · filed 2025-05-14 | -$1.19M 10-Q · filed 2024-05-09 | |||||
| 2023-12-31 | -$1.83M 10-K · filed 2025-03-28 | ||||||
| 2023-09-30 | -$2.71M 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | -$2.01M 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$1.10M 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | $3.71M 10-K · filed 2024-02-27 | ||||||
| 2022-09-30 | -$1.30M 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | -$978.85K 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | -$999.43K 10-Q · filed 2023-05-12 | ||||||
| 2021-12-31 | $807.09K 10-K · filed 2023-03-31 |